A Case With Ataxia, Optic Neuropathy and Polyneuropathy: Is There any Association With İmatinib or Natural Course of Chronic Myeloid Leukemia?

Year 2018, Volume: 10 Issue: 3, 89 - 90, 01.12.2018

Zeynep Gunes Ozunal Özlem Cam Sevki Sahin Esra Saglam Sibel Karsidag

Abstract

Imatinib is a tyrosine kinase inhibitor as a antineoplastic agent which is indicated in chronic myeloid leukemia CML , various hematologic and nonhematologic malignancies. Forty-seven years old male, with CML diagnosis 15 years ago and had stem cell transplantation 2 years ago and receiving radiotherapy and chemotherapy. After then, imatinib 400 mg daily is prescribed on for 12 months by the physician but patient himself continued for 15 months until he suspected drug when he has newly onset walking, swallowing difficulties and blurry vision. Imatinib and possible adverse drug reactions are discussed in the case presentation.

Keywords

Advers, chronic myeloid leukemia, imatinib, optik neuropathy

Bir Ataksi, Optik Nöropati ve Polinöropati Olgusu: İmatinib ile İlişkili mi Yoksa Kronik Miyeloid Löseminin Doğal Seyri mi?

Abstract

İmatinib kronik miyeloid lösemi KML ve birçok hematolojik ve nonhematolojik kanser tedavisinde kullanım endikasyonu olan bir tirozin kinaz inhibitörüdür. Bu yazıda, 15 yıl önce KML tanısı almış ve 2 yıl önce kök hücre nakli yapılmış ve radyoterapi ve kemoterapi görmüş 47 yaşındaki erkek hastanın, günde 400 mg imatinib 12 ay süreyle başlanmasından sonra, hastanın 15 ay devam etmesi ve sonrasında yeni başlangıçlı yürüme, yutma güçlüğü ve bulanık görme şikayeti ile başvurusu sunulmuş ve olgu imatinibin olası yan etki reaksiyonları açısından tartışılmıştır.

Keywords

Yan etki, kronik miyeloid lösemi, imatinib, optik nöropati

References

• 1. Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics: Targets & Therapy 2010; 4: 315–323.
• 2. https://www.uptodate.com/contents/ imatinib-drug information?source=search_ result&search=imatinib&selectedTitle=1~133, Accesed: 24/10/2017.
• 3. Ho WL, Wong H, Yau T. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophtalmol 2013;91:604-609.
• 4. Jain A, Gupta N. Isolated CNS Blast Crises in Chronic Myeloid Leukaemia Presenting as Hypertrophic Pachymeningitis and Bilateral Optic Neuritis: A Case Report. J Clin Diagn Res 2016; 10:1-5